Urteste plans to start clinical trials of diagnostic test for pancreatic cancer
19:14
Urteste plans to start clinical trials in the EU for Panuri, its pancreatic cancer diagnostic test, in Q3 2025. The company will select a CRO (Contract Research Organization) in the coming weeks to conduct the trials, which will involve 550 patients across Poland and selected EU countries. Parallelly, Urteste is preparing for FDA-regulated trials in the U.S., with a final Q-submission meeting scheduled for mid-2025.
The European study aims to accelerate certification and commercialization, providing early results faster than the U.S. trial. Urteste currently develops 12 diagnostic prototypes for cancers responsible for 70% of global cancer-related deaths. Their enzyme-based urine test technology enables early cancer detection through color changes in urine samples.
